Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector
Cambridge, UK, 4 March 2021 – Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and manufacturing capabilities are strengthening Abcam’s position as a leading collaborator for academia and industry in the region.
• Scaling up R&D, manufacturing and commercial capabilities in Shanghai and Hangzhou
• Investing in state-of-the-art facilities and equipment to support research, diagnostic and clinical applications
CEO at Abcam
The size of the Hangzhou facility has been increased by a third to meet the needs of strategic partners and customers focused on research, therapeutic, and in vitro diagnostic applications. With new automation and technology, fully flexible laboratory configurations and a specially designed logistics hub, the facility is driving the growth of Abcam’s high-quality, validated reagent portfolio. In addition, the new 10,000 sq ft Shanghai location is facilitating Abcam’s direct customer support across the region.
General Manager (Marketing and Sales) in China at Abcam
Abcam continues to strengthen its presence in the region through strategic partnerships and collaborations with key industry players. In January 2021 Abcam expanded its long-term strategic alliance with Shuwen Biotech, a leading Chinese company focusing on the development and commercialization of companion diagnostics for both China and ex-China.
The footprint expansion in China is an integral part of the Company’s commitment to sustainably deliver high-quality reproducible reagents to the global life science community.